The feasibility and acceptability of a physical activity intervention for older people with chronic musculoskeletal pain: The iPOPP pilot trial protocol by Healey, EL et al.
DOI: 10.1002/msc.1222R E S E A R CH AR T I C L EThe feasibility and acceptability of a physical activity
intervention for older people with chronic musculoskeletal pain:
The iPOPP pilot trial protocol*
E.L. Healey1 | C. Jinks1 | N.E. Foster1 | C.A. Chew‐Graham1 | T. Pincus1,2 | L. Hartshorne1 |
K. Cooke1 | E. Nicholls1 | J. Proctor1 | M. Lewis1 | S. Dent1 | S. Wathall1 | E.M. Hay1 |
J. McBeth1,31Arthritis Research UK Primary Care Centre,
Research Institute for Primary Care and Health
Sciences, Keele University, UK
2Department of Psychology, Royal Holloway,
University of London, Egham, UK
3Arthritis Research UK Centre for
Epidemiology, University of Manchester,
Manchester, UK
Correspondence
Dr Emma Healey, Arthritis Research UK
Primary Care Centre, Research Institute for
Primary Care and Health Sciences, Keele
University, Staffordshire, ST5 5BG, UK.
Email: e.healey@keele.ac.uk- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of th
the original work is properly cited.
© 2017 The Authors. Musculoskeletal Care publish
*This paper presents independent research funded b
for Leadership in Applied Health Research and Car
Musculoskeletal Care. 2017;1–15.Abstract
Introduction: This pilot trial will inform the design and methods of a future full‐scale random-
ized controlled trial (RCT) and examine the feasibility, acceptability and fidelity of the Increasing
Physical activity in Older People with chronic Pain (iPOPP) intervention, a healthcare assistant
(HCA)‐supported intervention to promote walking in older adults with chronic musculoskeletal
pain in a primary care setting.
Methods and analysis: The iPOPP study is an individually randomized, multicentre, three‐
parallel‐arm pilot RCT. A total of 150 participants aged ≥65 years with chronic pain in one or
more index sites will be recruited and randomized using random permuted blocks, stratified by
general practice, to: (i) usual care plus written information; (ii) pedometer plus usual care and writ-
ten information; or (iii) the iPOPP intervention. A theoretically informed mixed‐methods
approach will be employed using semi‐structured interviews, audio recordings of the HCA consul-
tations, self‐reported questionnaires, case report forms and objective physical activity data collec-
tion (accelerometry). Follow‐up will be conducted 12 weeks post‐randomization. Collection of
the quantitative data and statistical analysis will be performed blinded to treatment allocation,
and analysis will be exploratory to inform the design and methods of a future RCT. Analysis of
the HCA consultation recordings will focus on the use of a checklist to determine the fidelity
of the iPOPP intervention delivery, and the interview data will be analysed using a constant com-
parison approach in order to generate conceptual themes focused around the acceptability and
feasibility of the trial, and then mapped to the Theoretical Domains Framework to understand
barriers and facilitators to behaviour change. A triangulation protocol will be used to integrate
quantitative and qualitative data and findings.
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2 HEALEY ET AL.1 | INTRODUCTION
Musculoskeletal (MSK) pain is reported by 66% of older adults
(Thomas, Peat, Harris, Wilkie, & Croft, 2004). Patients with chronic
MSK pain have reduced physical activity (van den Berg‐Emons,
Schasfoort, Vos, Bussmann, & Stam, 2007) and pain is an important
predictor of physical inactivity (Plooij, van der Spek, & Scherder, 2012).
Physical activity reduces pain, improves quality of life and reduces
the risk of chronic illness in those with MSK pain (Der Ananian et al.,
2006). In older people, walking reduces pain and the risk of joint replace-
ment (Ageberg et al., 2012). Interventions to support increasedwalking in
older people with chronic MSK pain are appropriate, although the mech-
anisms to achieve this remain unclear. Developing such interventions is
challenging, as they need to address pain‐related factors such as fear of
injury (Cook, Brawer, & Vowles, 2006) and fear of falling (Hubscher, Vogt,
Schmidt, Fink, & Banzer, 2010). A recent systematic review concluded
that walking‐based exercise can be recommended for individuals with
chronic MSK pain, but further, robustly designed research with longer‐
term follow‐up is required (O'Connor et al., 2015).
Whether these review findings are transferable to the older
population is unclear. In older people, restricted mobility, limited time,
transportation and finance are barriers to participating in physical
activity interventions. Alternative methods of delivering support to
these individuals (e.g. telephone, email, text) could encourage them
to take part and adhere to an intervention. A recent walking interven-
tion for older adults with knee osteoarthritis demonstrated increased
adherence when supported according to preference (Loew et al.,
2017); therefore, it appears that choice is of importance to this
population. Interventions that also emphasize the evidence‐based,
dose–response nature of increasing individual physical activity (i.e.
“some is good, more is better”, irrespective of an individual's starting
point) may be beneficial (Ambrose & Golightly, 2015).
The National Institute for Health and Care Excellence (NICE) con-
cluded in their behaviour change guideline that interventions should incor-
porate a range of behavioural strategies, including goal setting, self‐
monitoring, self‐efficacy, support and relapse prevention (National Institute
for Health and Care Excellence, 2007). In order to maximize physical activ-
ity behaviour change, it is important that physical activity interventions are
successful at promoting self‐regulatory and volitional skills (drawing on
intentions as a vehicle to change) aswell as traditionalmotivational compo-
nents, such as self‐efficacy (Sniehotta, Scholz, & Schwarzer, 2006).
To facilitate roll‐out in primary care, interventions should be
acceptable and feasible to patients, intervention deliverers and the set-
ting in which they will be undertaken. Interventions also need to be
cost‐effective; selection of the intervention deliverer is vital. In primary
care, healthcare assistants (HCAs) are increasingly expected to provide
brief behaviour change advice on physical activity, weight manage-
ment, alcohol consumption and smoking cessation during NHS health
checks, and therefore may be suitable deliverers of a walking interven-
tion for older adults with chronic MSK pain, given appropriate training.2 | AIMS AND OBJECTIVES
The aims of the pilot trial are to test the design and methods of a
future full‐scale randomized controlled trial (RCT) and examine thefeasibility, acceptability and fidelity – the degree to which the
intervention is delivered as intended (Gearing et al., 2011) – of the
HCA‐supported Increasing Physical activity in Older People with
chronic Pain (iPOPP) intervention to promote walking in older adults
with chronic MSK pain in a primary care setting.
The objectives of the pilot trial are:
1. To determine the response rate of general practices to partici-
pate in the pilot trial.
2. To assess the feasibility and acceptability of the HCA‐supported
iPOPP intervention, with a particular focus on the HCAs'
experiences of delivering the intervention, and participants' expe-
riences of receiving the intervention.
3. To determine whether HCAs can be recruited, trained and
retained to deliver the iPOPP intervention for the pilot trial.
4. To assess fidelity of the HCA‐supported iPOPP intervention
delivery.
5. To estimate overall participant recruitment to the trial.
6. To estimate the short‐term follow‐up rate at 12 weeks across
trial arms and per treatment arm.
7. To examine the completion rates of the self‐reported outcome
measures (for primary and secondary outcome measures).
8. To estimate the parameters needed for a realistic sample size
calculation for a larger RCT.
9. To assess the feasibility and quality of collecting and analysing
objective physical activity data as the primary outcome data for
a future full‐scale trial, using accelerometers.
10. To integrate data analysis and findings from the quantitative and
qualitative evaluations, in order to identify changes required to the
trial design and intervention components ahead of a full‐scale trial.3 | METHODS
3.1 | Trial design and setting
The Standard Protocol Items for Randomized Trials (SPIRIT)
recommendations were followed in preparing this protocol (see Appen-
dix 1) (Chan et al., 2013). This is an individually randomized, multicentre,
three‐parallel‐arm pilot RCT recruiting 150 participants from four
general practices across Cheshire and the West Midlands, UK.
General practitioner (GP) practices are eligible to take part if they
use the clinical operating system EMIS Web (a clinical electronic
computer system for delivering healthcare which allows healthcare
professionals to record, share and use vital patient information), and
are willing to allow their employed HCAs to be trained and to deliver
the HCA‐supported intervention. General practice participation will
be formalized through written service level agreements.
3.2 | Trial population
Adults aged 65 years and over who have consulted at their general
practice in the last 12 months for MSK pain in one or more of the index
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for ≥3 months will be recruited to the trial. The full pilot trial eligibility
criteria are listed in Box 1.3.3 | Identification and screening of potentially
eligible participants
Members of the Clinical Research Network (CRN) Informatics Team
who are contracted to work in the participating general practices,
or the general practice staff will conduct a search of the computer-
ized consultation records, for adults aged 65 years and over who
have consulted with pain in at least one of the index sites in the last
12 months. The computerized record screen will identify patients
using Read codes (these are the standard clinical terminology coding
system used in general practice in the UK) that have been informed
by our previous research (Study of Work and Pain [SWAP] trial
ISRCTN 52269669 (Bishop et al., 2014); Management of OsteoAr-
thritis In Consultations [MOSAICS] trial ISRCTN: 06984617 (Dziedzic
et al., 2014)). In addition, the computerized record screening proto-
col will take into account aspects of the exclusion criteria where
possible (e.g. those in residential or nursing home accommodation
or those with congestive heart failure). From each practice, a GP willBox 1. Eligibility criteria for the physical activity in
older people with chronic pain (iPOPP) pilot trial
Inc lus ion cr iter ia
• Aged 65 years and over
• Registered with one of the participating general
practices during the specified trial period for that
practice
• Consulted at their general practice for a musculoskeletal
disorder in one or more index sites (foot, knee, hip, back,
shoulder or neck) in the last 12 months
• Pain that has lasted ≥3 months
• A chronic pain grade (von Korff, Ormel, Keefe, &
Dworkin, 1992) score of between 2 and 4, determined
through a brief postal chronic pain screening survey
• Able to provide full, informed, written consent
Exclusion cr iter ia
• Traumatic injury‐related pain (recent sports injury, fall or
accident) to rule out traumatic fractures
• Patients with complex medical conditions deemed at risk
of exercise‐related complications by their GP (e.g. chest
pain on exertion, severe hypertension, congestive heart
failure, syncope, uncontrolled epilepsy, recent fracture
(within the last 3 months), active and severe synovitis)be given the opportunity to review the list generated and exclude
those patients whom they consider inappropriate to be invited into
the trial, according to the trial exclusion criteria. CRN staff will then
administer an initial mailing phase in the form of a brief chronic
pain screening survey, to identify and screen potentially eligible
participants.
The screening survey will assess the eligibility criteria, enquire
about pain location and duration, determine the patient's Chronic Pain
Grade classification (von Korff et al., 1992) and confirm access to a
telephone (to enable further eligibility checking by a research nurse
and facilitate consent). Patients will be eligible to participate in the trial
if they have a Chronic Pain Grade classification of between 2 and 4 (i.e.
clinically significant mean levels of pain and functional difficulty)
(Foster et al., 2014).
Patients will return their screening survey to the Arthritis Research
UK Primary Care Centre and only those who are eligible and consent
to further contact will form the sample that are sent information about
the iPOPP trial.
3.4 | Approach and recruitment to the iPOPP trial
Those who meet the eligibility criteria and who agree to further
contact will be posted an iPOPP trial pack (a cover letter, a patient
information sheet, a baseline questionnaire and a freepost return
envelope). Patients will then be contacted by a CRN nurse by
telephone to confirm eligibility and willingness to participant within
10 working days. Those who wish to take part in the trial will be
asked to sign and date the written consent form (see Appendix 2)
and return it, along with the completed baseline questionnaire, to
the study team in a pre‐paid envelope. On receipt of the written
informed consent form and baseline questionnaire, each participant
will be sent an accelerometer in the post for baseline data
collection. Once accelerometry data collection is complete (7 days)
and the accelerometer is returned to the research centre, participants
will be randomized. Figure 1 summarizes the participant recruitment
for the iPOPP trial.
3.5 | Randomization
Participants will be randomized to one of the three interventions using
third‐party computerized randomization supported by Keele Clinical
Trials Unit (CTU). To ensure that participants at each general practice
have an equal chance of receiving any of the interventions, participants
will be individually randomized using random permuted blocks, strati-
fied by general practice.
The GP of each participant will be sent a letter to confirm that
their patient is taking part in the trial, unless the participant does not
provide consent for this.
3.6 | Allocation concealment, blinding and selection
bias
A CRN nurse blind to subsequent treatment allocation will obtain
informed consent. Selection bias at recruitment will be avoided by
separating the processes of determining patient eligibility and
intervention allocation. The trial database will be password protected,
FIGURE 1 Flow chart demonstrating recruitment of participants into the iPOPP trial
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questionnaire and accelerometry data collection remain blind to
treatment allocation. Allocation concealment and blinding is not possi-
ble for the participants or HCAs; however, the HCAs will deliver only
one of the three trial interventions. Data entry, coding, security, stor-
age and management will follow the standard operating procedures
at Keele CTU.
3.7 | The interventions
Each of the three interventions are detailed below:
1. Usual care: Participants randomized to this intervention will be
sent some high‐quality written information in the form of the paintoolkit (http://www.paintoolkit.org) in the post by the study team,
and will continue to be managed via usual care. The pain toolkit is
a simple booklet that provides participants with tips and advice to
support them in managing their pain. Usual primary care
management normally consists of a patient consulting their GP
or practice nurse for their pain, and may include advice and
education, the prescription of medication and referrals to other
appropriate services, such as physiotherapy, podiatry or occupa-
tional therapy.
2. Usual care plus pedometer: Participants randomized to this
intervention will continue with their usual care, and in addition
will receive in the post a pedometer, a pedometer user guide
based on the NICE guidance on promoting walking (National
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and the pain toolkit.
3. iPOPP walking intervention: When a participant is randomized
to this intervention, the trial coordinator will pass on contact
details to the relevant trained HCA. The HCA will then contact
the participant to arrange their first consultation. The aim of this
intervention is to initiate and support adherence to a walking
plan. In brief, participants allocated to this intervention arm will
be offered an initial appointment for a face‐to‐face consultation
at their general practice with a trained HCA. At this first consul-
tation, participants will receive a pedometer, the user guide and
a walking diary plus a copy of the pain toolkit. The consultation
(approximately 30 min) will include two components. The moti-
vational stage will draw on motivational interviewing techniques,
to prompt the patient to make self‐motivating statements about
walking behaviour. Then, in the action planning stage, volitional
techniques will be used to facilitate realistic walking goals, to
help to translate intentions into practice (e.g. setting specific,
measurable, achievable, realistic, time‐related [SMART] goals
and drawing on the use of the pedometer). Participants will be
encouraged to identify places (e.g. the local park, their home)
where they can accumulate steps over the course of a day.
Important barriers to walking specific to the individual, such as
pain‐related fear of movement, will be addressed. Participants
will receive a second consultation about 2 weeks later (approx-
imately 30 min) either face to face or via telephone (depending
on participant preference), consisting of a review of progress
since the first consultation, positive feedback in relation to
effort and achievement, possible revision of goals set, and
relapse prevention strategies (e.g. support from friends/family,
identifying a walking “buddy”). Participants will then receive
eight weekly motivational prompts, which will be in the form
of a postcard, email or text (dependent on patient preference).
Participants allocated to this intervention arm will also continue
to access usual care (as described above). Each HCA will use a
case report form (CRF) to record what happened during the
two intervention consultations, how they were delivered (face
to face or telephone), the dates of the consultations and the
agreed method for the eight weekly motivational prompts (post-
card, text or email). This information will be sent by the HCA
back to the study team and logged on the trial database. The
start of the weekly prompts will be initiated by the trial
database.4 | DEVELOPMENT OF THE HCA TRAINING
The development and content of the HCA‐supported iPOPP interven-
tion training will be reported elsewhere. In brief, the development of
the HCA training programme will, in line with previous research, con-
sist of four phases (French, Stevenson, & Michie, 2012; Healey et al.,
2015; Porcheret et al., 2014): (i) defining the content; (ii) selecting
the behaviour change techniques; (iii) deciding on the style of delivery;
and (iv) addressing local practicalities. It is anticipated that at least oneHCA will be trained to deliver the HCA‐supported iPOPP intervention
per practice and that the training will take place in a group setting over
2 days, 1 week apart, to allow the HCAs to absorb and reflect on what
they have learnt, re‐read intervention materials and complete “home-
work” before further review training. All HCA time taken to attend
the training and deliver the intervention will be reimbursed to the
general practice that employs them. All HCAs that attend the training
will be asked to complete a pre‐ and post‐training evaluation question-
naire, focused on assessing knowledge and confidence to deliver the
iPOPP intervention.5 | OUTCOMES
In order to achieve the aims and objectives set out for this pilot trial, a
theoretically informed mixed‐methods approach, including semi‐
structured interviews, audio recordings of the HCA consultations,
participant self‐reported questionnaires, CRFs, and accelerometry
data collection, will be undertaken. These methods of data collection
will help to inform the design and methods of a future full‐scale RCT
and examine the feasibility, acceptability and fidelity of the HCA‐
supported intervention (iPOPP) in a primary care setting.5.1 | Qualitative data collection
Audio recordings of a sample of HCA consultations (including both first
and second consultations) and semi‐structured interviews with all
HCAs and a sample of participants will form the basis of the qualitative
data collection.
5.1.1 | Audio‐recording of the HCA‐supported iPOPP
intervention consultations
A sample of the first and second HCA consultations will be digitally
audio‐recorded, with HCA and participant consent. These audio
recordings will focus on the fidelity of the iPOPP intervention delivery
– for example, which elements of this intervention the HCAs used,
whether the training was reflected in HCA behaviour and whether
there are any gaps in intervention delivery.
Each HCA trained (n = 6) to deliver the iPOPP intervention will be
asked to record a total of six consultations, with three participants (ide-
ally three first and three second consultations). The team will therefore
have a minimum of 36 recorded consultations. A digital recorder will be
used, and switched on by the HCA at the start of the consultation.
Fully informed consent from the participant for the recording of both
consultations with the HCA will be obtained by a member of the study
team.
5.1.2 | Semi‐structured interviews
Semi‐structured interviews will be conducted with a sample of partic-
ipants (pedometer and iPOPP interventions only) and all trained HCAs.
The interviews with participants will explore the acceptability and
credibility of the pedometer and iPOPP interventions, whether walking
has been continued, barriers and facilitators to maintaining or increas-
ing walking, and prior experience of consulting with HCAs (iPOPP
intervention only).
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oped their knowledge and skills to enable them to deliver the interven-
tion, how the training could be improved and the factors that helped or
hindered the implementation and delivery of the intervention to the
target population.
HCAs
All of the HCAs (n = 6) trained to deliver the iPOPP intervention will be
invited to participate in individual telephone or face‐to‐face semi‐
structured interviews at the end of the intervention period. A topic
guide will stimulate dialogue in the interview and allow an exploration
of the acceptability and operationalizing of the training and the iPOPP
intervention.
Trial participants
A sample of participants across the four practices, from the pedometer
and iPOPP interventions only, will be invited to participate in a semi‐
structured interview after the 12‐week follow‐up data collection is
complete. We will specifically sample participants who completed
and dropped out of the iPOPP intervention, to explore reasons for
completion and drop‐out. A sample will be selected from the pedome-
ter intervention purposively, based on practice, age and gender, to
ensure a broad range of participants. Approximately 10–15 partici-
pants per intervention will be interviewed; data collection will be con-
tinued until category saturation is achieved in each group.
All interviews and audio recordings of the iPOPP intervention will
be digitally recorded, with consent, and will be professionally tran-
scribed verbatim. This will form the data for analysis.5.2 | Quantitative data collection
Accelerometry data, self‐reported questionnaires, and individual CRFs
(iPOPP intervention only) will form the basis of the qualitative data
collection.
5.2.1 | Accelerometers
This trial will primarily use these objective physical activity monitors
to estimate levels of physical activity via average daily step count.
Number of counts per minute, time spent sedentary, time spent in
light, moderate and vigorous physical activity, and proportions of
people who meet guideline levels of physical activity will also be esti-
mated (Department of Health., 2011; Foster et al., 2014; Lee et al.,
2015). This pilot trial is not powered to detect clinically relevant dif-
ferences between the interventions in walking, and these data will
not be used as criteria for progression to a full trial. However, we will
collect data on the feasibility of using accelerometers as the primary
outcome in our target population for a full‐scale trial. The waist‐worn
triaxial accelerometer units (wGT3X‐BT monitor, Actigraph,
Pensacola, FL, USA) will be pre‐programmed and posted out to the
participants with full instructions, once consent to the trial is
received but prior to randomization, and again at the 12‐week fol-
low‐up. Participants will be asked to wear the unit for 7 consecutive
days on their waist during waking hours, and then to post the unit
back to the research centre, where the data collected will be
downloaded and analysed if participants have worn theaccelerometer on at least 5 days, for 10 h or more each day
(assuming that consecutive runs of zero count for 60 min or more
are “non‐wear”) (Foster et al., 2014). To maximize response rates,
participants will receive up to two reminder telephone calls and a
reminder postcard, asking them to return the units if they are not
returned within 4 weeks after the end of data collection.5.2.2 | Self‐reported questionnaires
All participants will be asked to complete a self‐report questionnaire at
two time points: at baseline and at 12 weeks post‐randomization.
Participants will return the questionnaires to the research centre in
pre‐paid envelopes. To maximize response rates to the follow‐up
questionnaire, participants will receive a reminder telephone call and
then sent a reminder postcard if it is not returned within 2 weeks. If
the follow‐up questionnaire is not received following these reminders,
participants will receive a telephone call to ask them to provide a min-
imum dataset over the telephone (see Table 1).
The baseline questionnaire will collect information on partici-
pant characteristics (e.g. gender, age, pain sites, co‐morbidity,
employment status). Questionnaire measures (at baseline and 12‐
week follow‐up) of physical functioning and mental health (The
EQ‐5D‐5L) (Herdman et al., 2011), pain intensity (Numerical Rating
Scale) (Ostelo & de Vet, 2005), pain location (pain manikin) (Lacey
et al., 2014), physical activity (International Physical Activity Ques-
tionnaire for the Elderly (Hurtig‐Wennlo, Hagströmer, & Olsson,
2010) and the Self‐Efficacy for Exercise Scale (Resnick & Jenkins,
2000) will be collected.
The 12‐week follow‐up questionnaire will also collect information
on any adverse events experienced during the trial, and include a mod-
ified version of the treatment acceptability and credibility measure
developed by Borkovec and Nau (1972), with four items each mea-
sured using a 10‐point scale. This measure will help us to investigate
the acceptability and credibility of the HCA‐supported iPOPP
intervention to older people with chronic MSK pain, by assessing
how logical it seems to participants, how confident participants are
that it will be successful in managing chronic pain, how confident par-
ticipants would be in recommending it to a friend and how successful
participants feel it would be for another pain problem. Table 1 summa-
rizes all data collection methods and their respective time points.5.2.3 | Individual CRFs
The CRFs will be audited by the study team during the intervention
delivery phase, to ensure that the HCA‐supported iPOPP
intervention is being delivered per protocol and to identify any fur-
ther training requirements. The CRFs will also be examined at the
end of the pilot trial, to help to assess the fidelity of the iPOPP inter-
vention delivery.6 | PILOT TRIAL SUCCESS CRITERIA
The following criteria will be used to judge the success of the pilot trial,
in order to make decisions about a future full‐scale trial:
TABLE 1 Types and timing of data collection for the physical activity in older people with chronic pain (iPOPP) pilot trial




















Chronic pain grade (von Korff et al., 1992) ✓
Co‐morbidity ✓
Primary outcome measure




Modified version of treatment acceptability and
credibility measure (Borkovec & Nau, 1972)
✓ ✓ (MDC)
Physical functioning and mental health
(EQ‐5D‐5 L) (Herdman, Gudex, & Lloyd, 2011)
✓ ✓
Pain intensity Numerical Rating Scale
(Ostelo & de Vet, 2005)
✓ ✓
Pain location (body manikin) (Lacey et al., 2014) ✓
International physical activity questionnaire for
the Elderly (Hurtig‐Wennlo et al., 2010)
✓ ✓ ✓ (MDC)




HCA‐supported intervention case report form ✓ ✓
Sample of consultation audio recordings ✓ ✓
Semi‐structured interviews – HCA ✓
Sample of semi‐structured interviews –
Participant
✓
EQ‐5D‐5 L, 5‐level European Quality of Life–5 Dimensions; HCA, healthcare assistant; MDC, minimum data collection.
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low‐up, whereby the mean score for participants randomized to
the HCA‐supported intervention should be at least 5 to progress
to a full trial.
2. Recruitment rates of at least 70% predicted (n = 150).
3. Follow‐up rates of at least 70% of those randomized at the 12‐
week follow‐up.
4. An acceptable intervention adherence rate (at least 50% of those
receiving the HCA‐supported iPOPP intervention will complete
the two consultations).7 | SAMPLE SIZE
This is a pilot trial, and a formal sample size calculation is not appropriate.
However, for pilot studies it has been recommended that the dataset
should comprise a minimum of 30 participants in each arm (Shih,
Ohman‐Strickland, & Lin, 2004). We anticipate that the combined total
loss to follow‐up and non‐adherence to the iPOPP intervention will beno more than 30% at the 12‐week follow‐up (i.e. 20% due to loss to
follow‐up and 10% due to non‐compliance) and therefore aim to recruit
50 participants in each arm, to account for potential missing data. Part of
the rationale of a pilot is to gather data to inform the design of a full trial;
therefore, more robust estimates for non‐compliance and loss to follow‐
up rates in this patient group will be generated by the end of the pilot
study and will inform power calculations for a potential full trial.
To determine the number of persons to be mailed the chronic pain
screening survey, to identify the 150 participants for this pilot trial, as a
guide, we have used data from previous RCTs and observational studies
with older adults with MSK pain (e.g. the Self‐Management in OA of the
Hand [SMOOTH] trial (Dziedzic et al., 2011), benefits of effective exercise
for knee pain (BEEP) trial (Foster et al., 2014)). To obtain at least 150 eli-
gible adult participants aged 65 and over, wewill target at least 800 adults
aged 65 and over who have consulted their GP for MSK pain in the index
sites in the last 12 months. Based on previous trials, we anticipate that
approximately 400will respondwith a completed questionnaire, of whom
150 will fulfil eligibility criteria and consent to participate in the trial, and
approximately 105will provide 12‐week follow‐up data. Four typical gen-
eral practice sizes in excess of 7,000 should provide a sufficient sampling
frame from which to ascertain the required numbers for this pilot trial.
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CONSIDERATIONS
The iPOPP pilot trial will be monitored in line with the protocol and
Keele CTU standard operating procedures. An independent trial
steering committee will monitor the progress of the trial and a data
monitoring committee will be convened to monitor the safety of
participants and data integrity. Monitoring will also be undertaken by
the research ethics committee and the funder (Arthritis Research UK)
in the format of annual progress reports.
All HCAs at participating general practices must report any
significant events that they become aware of that occur during the
12‐week period over which a patient is participating in the trial (i.e.
12 weeks from the date of randomization). All participants will also
be provided with the contact details of the trial coordinator and asked
to self‐report any such events to the trial team as soon as possible.
Participants randomized to the HCA‐supported iPOPP intervention
will see or speak to an HCA at the first and second consultation. HCAs
will ask participants about, record and report any significant events
that they become aware of to the trial team. As the risk of related
unexpected serious adverse events (SAEs) is low in this study, HCAs
will not be trained in SAE definitions. They should instead report signif-
icant events – for example, a participant needing to be admitted to
hospital, a fall or any problem which needed medical treatment to
prevent the participant being admitted to hospital. Safety reporting
procedures will be covered during HCA training sessions, and a copy
of the procedure will be filed in the site file. We will also ask partici-
pants in their 12‐week follow‐up questionnaire if they perceive that
they have experienced any adverse events during the trial period.
If a potential SAE is reported to a member of the trial team, this
information will be passed to the study coordinator at Keele CTU,
who will ensure that the necessary paperwork is completed and inform
the trial chief investigator and trial GP immediately. The trial GP will
assess whether any reported SAEs were related to the trial interven-
tion, according to the process laid out in Keele CTU's standard operat-
ing procedure. Any unexpected SAEs considered to be related to the
trial procedures will be reported to the research ethics committee by
the chief investigator within 15 days of becoming aware of the event.
In addition, all related unexpected SAEs will be reported to Keele Uni-
versity (as the trial sponsor), the trial steering committee and the data
monitoring committee.9 | ANALYSIS
9.1 | Qualitative data
Researchers from the qualitative team will examine the audio record-
ings of the iPOPP intervention consultations and use an intervention
fidelity checklist specifically developed for the trial to assess whether
components of the consultation intended to be included, and focused
on during training, were demonstrated by the HCA.
The interviews with HCAs and trial participants will be transcribed
and the data analysed by members of the study team, adopting a con-
stant comparison approach (Glaser, 1965; Hallberg, 2006), with initialcoding of text segments, followed by re‐coding and memo writing in
order to generate conceptual themes. The study team will then discuss
and agree on overarching thematic interpretations. A framework
approach will then be used to facilitate interpretation of the data
(Richie & Spencer, 1994). Analysis will be conducted by researchers
from different professional backgrounds, to improve the trustworthi-
ness of the analysis (Henwood & Pigeon, 1992). Following initial induc-
tive analysis, themes will be mapped to behavioural theory by using the
Theoretical Domains Framework (Atkins et al., 2017; Michie et al.,
2005) to identify influences on behaviour that have an impact on
implementation of the iPOPP intervention.9.2 | Quantitative data
The analysis of the quantitative data will be exploratory and provide
further data on the feasibility and acceptability of the HCA‐supported
intervention, and the design and methods of a full‐scale RCT. For
example, findings from the pilot trial might inform required changes
in the trial recruitment processes, data collection processes and
outcome measures Participant characteristics (e.g. gender, age, pain
sites, co‐morbidity, employment status), self‐reported at baseline, will
be compared by intervention arm and by general practice to explore
the balance of patient characteristics. These data will also allow any
evidence of selection bias to be assessed by comparing consenting
and non‐consenting individuals, withdrawals, drop‐outs and
completers. The percentage of participants consenting to take part in
the trial and follow‐up rates for the post‐intervention follow‐up
questionnaire per intervention group will also be examined.
Completion rates of the self‐reported outcome measures will be
reported, to identify any that are poorly completed. The content of
the self‐reported questionnaire for a full RCT will be adapted
accordingly.
Data from the pilot study will also be used to help to inform a sam-
ple size calculation for the full‐scale trial, for the primary outcome of
interest (step counts measured using accelerometry). This estimate will
be viewed cautiously, however, given that there are only four practices
included in the pilot trial. Participants will only be included in this
analysis if they have worn the monitor for at least 5 days, for 10 h or
more each day. Valid time will be calculated assuming that any consec-
utive runs of zero count lasting for 60 min or more are counted as
“non‐wear” (Foster et al., 2014). For each participant, we will generate
the following: average daily step count, and the proportion of time
spent sedentary and in light, moderate and vigorous physical activity,
using the cut‐offs from Lee et al. (2015) and Freedson, Melanson,
and Sirard (1998), and the proportions of people who meet guideline
levels of physical activity for older adults will also be calculated
(Department of Health, 2011).9.3 | Integrating quantitative and qualitative data
and findings
When the analysis of the quantitative and qualitative data is com-
plete, a triangulation protocol (O'Cathain, Murphy, & Nicholl, 2010;
Tonkin‐Crine et al., 2016) will be used. This technique enables inte-
gration of data in order to investigate the completeness, convergence
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Elliott, & Eyles, 2006). Methods include following a thread and devel-
opment of a convergence coding matrix. The matrix allows findings
from different study components to be displayed side by side. Inte-
gration will aid interpretation of findings and inform decisions about
changes to trial processes or intervention components ahead of a
full‐scale trial.10 | PATIENT AND PUBLIC INVOLVEMENT
AND ENGAGEMENT (PPIE)
The pilot trial design and processes have been informed by patient and
public involvement, in line with our centre's strong commitment to
involving the public in research (Jinks, Carter, et al., 2016), following
INVOLVE's recommendations (http://www.invo.org.uk/resource‐cen-
tre/resource‐for‐researchers/).
A lay co‐applicant helped with the iPOPP pilot trial funding
application. For the development phase of the iPOPP pilot trial
(intervention and training development), two members of the public
attended a stakeholder workshop in January 2015 and 11 members
of the public attended a nominal group technique meeting held in
February 2015 (Jinks, Healey, et al., 2016). These individuals were
selected as they were aged 65 years and over and reported having
chronic pain, and were recruited from local third‐sector groups such
as Age UK and The Beth Johnson Foundation, which are charities
working towards a positive impact on the lives of older people. We
have also involved our PPIE group at the Arthritis Research UK Primary
Care Centre, which is made up of patients and members of the public
with different MSK conditions, in the assessment our participant infor-
mation (letters of invitation, participant information sheets, question-
naires), and their feedback will be incorporated into the final
versions. Two members of the iPOPP pilot trial steering committee will
be lay members. All research users are supported by a user support
worker and a PPIE coordinator through regular meetings and an annual
conference at Keele University.11 | ETHICS AND DISSEMINATION
The pilot trial has been approved by the West Midlands – Solihull
Research Ethics Committee (REC reference: 15/WM/0329).
All participating general practices will receive a poster at the end
of the study, which they can display in order to inform participants
of the pilot trial results. In addition, all participants will be informed
of the results personally by post. The results of this study will be
reported to the trial steering committee, data monitoring committee
and our funder, published in relevant high‐quality peer‐reviewed
journals and presented at national and international conferences.12 | TRIAL MONITORING
The trial steering committee met prior to ethics application in order to
agree the final protocol, and at agreed time intervals over the course of
the pilot trial. The data monitoring committee also reviewed the studyprotocol and receive reports at agreed intervals. All data collection,
database design, data input and cleaning, as well as trial oversight pro-
cedures, will be in line with the standard operating procedures of the
Keele CTU and the conditions of the grant.13 | DATA CONFIDENTIALITY AND
ARCHIVING
All pilot trial‐related information will be stored securely at the Arthritis
Research UK Primary Care Centre at Keele University. Data will be
anonymized using coded identification numbers, with the housing of
the data and the linking code in separate locations, under password
protection. Access to the data will be restricted to individuals involved
in audit and analysis. The data from the pilot trial will be archived and
made available for future, secondary analysis and data pooling pur-
poses from the Arthritis Research UK Primary Care Centre at Keele
University.
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documentsa.
Section/item Item no Description Addressed on page number
Introduction
Background and rationale 6a Description of research question and justification for
undertaking the trial, including summary of relevant studies
(published and unpublished) examining benefits and harms
for each intervention
4‐5___________
6b Explanation for choice of comparators 4‐5___________
Objectives 7 Specific objectives or hypotheses 5____________
Trial design 8 Description of trial design, including type of trial (e.g. parallel
group, crossover, factorial, single group), allocation ratio
and framework (e.g. superiority, equivalence,
noninferiority, exploratory)
5__________
Methods: Participants, interventions and outcomes
Study setting 9 Description of study settings (e.g. community clinic, academic
hospital) and list of countries where data will be collected.
Reference to where list of study sites can be obtained
7____________
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable,
eligibility criteria for study centres and individuals who will
perform the interventions (e.g. surgeons, psychotherapists)
7____________
Interventions 11a Interventions for each group with sufficient detail to allow
replication, including how and when they will be
administered
10‐11_________
11b Criteria for discontinuing or modifying allocated interventions
for a given trial participant (e.g. drug dose change in
response to harms, participant request or improving/
worsening disease)
N/A__________
11c Strategies to improve adherence to intervention protocols,
and any procedures for monitoring adherence (e.g. drug
tablet return, laboratory tests)
10‐11_________
11d Relevant concomitant care and interventions that are
permitted or prohibited during the trial
N/A_________
Outcomes 12 Primary, secondary and other outcomes, including the specific
measurement variable (e.g. systolic blood pressure),
analysis metric (e.g. change from baseline, final value, time
to event), method of aggregation (e.g. median, proportion),
and time point for each outcome. Explanation of the clinical
relevance of chosen efficacy and harm outcomes is strongly
recommended
12‐17_________
Participant timeline 13 Time schedule of enrolment, interventions (including any run‐
ins and washouts), assessments, and visits for participants.
A schematic diagram is highly recommended (see Figure 1)
Figure 1_____
Sample size 14 Estimated number of participants needed to achieve study
objectives and how it was determined, including clinical and
statistical assumptions supporting any sample size
calculations
17‐18_________
Recruitment 15 Strategies for achieving adequate participant enrolment to
reach target sample size
8‐9___________
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (e.g. computer‐
generated random numbers), and list of any factors for
stratification. To reduce the predictability of a random
sequence, details of any planned restriction (e.g. blocking)
should be provided in a separate document that is
unavailable to those who enrol participants or assign
interventions
9___________
Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (e.g.
central telephone; sequentially numbered, opaque, sealed
envelopes), describing any steps to conceal the sequence
until interventions are assigned
9____________
Implementation 16c Who will generate the allocation sequence, who will enrol
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documentsa.
Section/item Item no Description Addressed on page number
Blinding (masking) 17a Who will be blinded after assignment to interventions (e.g.
trial participants, care providers, outcome assessors, data
analysts), and how
9____________
17b If blinded, circumstances under which unblinding is
permissible, and procedure for revealing a participant's
allocated intervention during the trial
N/A__________
Methods: Data collection, management and analysis
Data collection methods 18a Plans for assessment and collection of outcome, baseline and
other trial data, including any related processes to promote
data quality (e.g. duplicate measurements, training of
assessors) and a description of study instruments (e.g.
questionnaires, laboratory tests), along with their reliability
and validity, if known. Reference to where data collection
forms can be found, if not in the protocol
12‐17_________
18b Plans to promote participant retention and complete follow‐
up, including a list of any outcome data to be collected for
participants who discontinue or deviate from intervention
protocols
14‐17_________
Data management 19 Plans for data entry, coding, security and storage, including
any related processes to promote data quality (e.g. double
data entry; range checks for data values). Reference to
where details of data management procedures can be
found, if not in the protocol
20‐23_________
Statistical methods 20a Statistical methods for analysing primary and secondary
outcomes. Reference to where other details of the
statistical analysis plan can be found, if not in the protocol
20‐23_________
20b Methods for any additional analyses (e.g. subgroup and
adjusted analyses)
N/A__________
20c Definition of analysis population relating to protocol non‐
adherence (e.g. as randomized analysis), and any statistical
methods to handle missing data (e.g. multiple imputation)
N/A__________
Methods: Monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary
of its role and reporting structure; statement of whether it
is independent from the sponsor and competing interests;
and reference to where further details about its charter can
be found, if not in the protocol. Alternatively, an
explanation of why a DMC is not needed
23__________
21b Description of any interim analyses and stopping guidelines,
including who will have access to these interim results and
make the final decision to terminate the trial
N/A__________
Harms 22 Plans for collecting, assessing, reporting and managing
solicited and spontaneously reported adverse events and
other unintended effects of trial interventions or trial
conduct
16,19_______
Auditing 23 Frequency and procedures for auditing trial conduct, if any,
and whether the process will be independent from
investigators and the sponsor
N/A__________
Ethics and dissemination
Research ethics approval 24 Plans for seeking research ethics committee/institutional
review board (REC/IRB) approval
23__________
Protocol amendments 25 Plans for communicating important protocol modifications (e.
g. changes to eligibility criteria, outcomes, analyses) to
relevant parties (e.g. investigators, REC/IRBs, trial
participants, trial registries, journals, regulators)
N/A_________
Consent or assent 26a Who will obtain informed consent or assent from potential
trial participants or authorised surrogates, and how (see
item 32)
8____________
26b Additional consent provisions for collection and use of
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(Continued)
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documentsa.
Section/item Item no Description Addressed on page number
Confidentiality 27 How personal information about potential and enrolled
participants will be collected, shared and maintained in
order to protect confidentiality before, during and after the
trial
23‐24_________
Declaration of interests 28 Financial and other competing interests for principal
investigators for the overall trial and each study site
25__________
Access to data 29 Statement of who will have access to the final trial dataset,
and disclosure of contractual agreements that limit such
access for investigators
24__________
Ancillary and post‐trial care 30 Provisions, if any, for ancillary and post‐trial care, and for
compensation to those who suffer harm from trial
participation
N/A_________
Dissemination policy 31a Plans for investigators and sponsor to communicate trial
results to participants, healthcare professionals, the public,
and other relevant groups (e.g. via publication, reporting in
results databases or other data sharing arrangements),
including any publication restrictions
23__________
31b Authorship eligibility guidelines and any intended use of
professional writers
N/A_________
31c Plans, if any, for granting public access to the full protocol,
participant‐level dataset and statistical code
N/A_________
Appendices
Informed consent materials 32 Model consent form and other related documentation given
to participants and authorized surrogates
Appendix 2____
Biological specimens 33 Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in the
current trial and for future use in ancillary studies, if
applicable
N/A_________
aIt is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the
items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
“Attribution‐NonCommercial‐NoDerivs 3.0 Unported” licence.
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CONSENT FORM
